Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
Status:
Recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, Phase 1b study with dose escalation and expansion cohorts designed to
assess the safety, tolerability, PK, and preliminary efficacy of PU-H71 in subjects with PMF,
Post-PV MF, Post-ET MF, taking stable doses of ruxolitinib.